The use of L-dopa in the treatment of Parkinsonism represents a great advance but we are becoming increasingly aware of the problems involved with its lo.ng-term use-side effects, abnormal involuntary movements, diurnal oscillations in performance ("on-off" effects), and loss of therapeutic efficiency after several years' treatment. Therefore, other substances are being sought to replace or to be used in conjunction with L-dopa. It is for these reasons that dopaminergic agonists have been synthesised: apomorphine, piribedil, lergotrile, N-propyl-aporphine and, more recently, bromocriptine (CB 154 Sandoz; Parlodel).
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First used for its inhibitory properties on prolactin secretion, bromocriptine also stimulates the postsynaptic (Corrodi et al., 1973) and presynaptic (Snider et al., 1976) central dopaminergic receptors which renders it suitable for the treatment of Parkinson's disease. Bromocriptine also seems to have a stimulating action on the serotoninergic receptors (Corrodi et al., 1975; Snider et al., 1976) .
Since the first clinical trials done by Calne and co-workers (1974a, b) , bromocriptine has been the object of numerous studies. It improves the extrapyramidal symptoms (mainly tremor and rigidity) not only at low doses (20 to 30 mg) in conjunction Bromocriptine was prescribed (in tablet form at 2.5 mg per tablet) at 5 mg the first day which was increased by 5 mg every three days. Above a dose of 5 mg, increases were made by daily steps of 2.5 mg until maximum dosage which increased throughout the trial. At the beginning of the study, the maximum dose was fixed at 30 mg, then because of the satisfactory tolerance observed and of data being published, we used higher doses without exceeding 75 mg per day.
Bromocriptine was used as the only treatment whenever possible. In patients who had never received L-dopa treatment, bromocriptine was used alone. In cases where previous treatment had involved the use of L-dopa, with or without inhibitor), substitution was always tried. When the effect of bromocriptine was insufficient, L-dopa was added in moderation until the desired effect was reached.
Each patient was followed by at least two doctors familiar with the therapy being used. The degree of akinesia, rigidity, and tremor and also the functional performance were evaluated, using a staging scale with four increasing levels (0, 1, 2, and 3), before bromocriptine treatment, and during each consultation-that is, every month for three months-then every other month for nine months, and every six months thereafter. At each of these examinations, the main biological constants (blood and urinary) were measured, and an electroencephalogram recorded.
The results were judged using our staging scale: excellent-if, regardless of the initial seriousness of the clinical symptoms, the score returned to zero; good-if the improvement showed a twopoint change without disappearance of clinical signs; average-for a one point improvement; mediocre-for absence of objective change but with a subjective improvement; useful-for a therapeutic value equivalent to that of L-dopa but with reduced side effects; failure-corresponding to either intolerance or to ineffectiveness of the drug.
The experiment was begun in October 1975. The study lasted for 5-29 months-that is, six cases of 5-10 months, nine cases of 10-15 months, six cases of 15-20 months, and 13 cases of 20-29 months. All the patients were seen at the end of March 1978. Two patients died of unrelated causes in the third and fifteenth months.
Results
The results are separated into four groups: group 1 included 12 patients who had never received regular L-dopa treatment, either because it was never attempted or because of intolerance from the outset-they are described as non-dopa patients; group 2 was comprised of 18 patients who had shown themselves incompatible with longterm therapy with L-dopa; group 3 included 11 patients with "on-off" effects after long-term treatment with L-dopa; and group 4 contained three patients in whom all anti-Parkinsonism treatment had ceased to be effective.
NON-DOPA PATIENTS
This group was made up of 12 patients (four men and eight women, one of whom had postencephalitic Parkinson's disease) who had never received L-dopa treatment for any length of time. Six of the patients had never been treated with L-dopa. The six others were intolerant to L-dopa from the outset because of various complications: cardiovascular (one case), digestive (two cases), acute headache (one case), dizziness (one case), attacks of generalised contractions (one case).
The results are shown in Table 2 . We obtained six excellent results using bromocriptine doses of between 20 and 75 mg. These six patients continued their long-term bromocriptine monotherapy without the need to add other treatment. The result is stable and, until the time of reporting, the treatment is still effective. In four cases (6, 7, 28, and 40 ) the persistence of tremor made the addition of anticholinergics necessary. The levels of bromocriptine were kept moderate (25 to 30 mg) since these were the first patients to be treated, and it was thought best not to raise the dose too high. Hoehn and Yahr (1967) . **Antichol = anticholinergics.
tDied during treatment (unrelated illness).
It was with this group that we were able to see the action of this compound on the Parkinsonism symptoms. Using our staging scale, we noticed that akinesia and hypertonia were most favourably affected (+53.5%) and tremor to a lesser degree (+32%). The functional performance was improved by more than 50% on average ( Figure) .
In two cases (8 and 10), the use of low doses of bromocriptine (25 and 30 mg) did not bring about a satisfactory control of extrapyramidal symptoms. In one of them (10), bromocriptine treatment was stopped while in the other patient Lees et al. (1975) (11 patients) and Parkes et al. (1976) (10 patients). These authors had few failures-for Lees, two cases, one of whom had Shy-Drager syndrome, and none for Parkes. In their experiments, the average dose was 40 mg which is slightly higher than the one we used. We were unable to find a correlation between the effectiveness of bromocriptine and the degree or duration of illness. Parkes et al. (1976) , however, state that they obtained better results with less severe forms, and Lieberman et al. (1976a) observed greater effectiveness of bromocriptine on more recently contracted conditions. Bromocriptine was effective for long-term treatment in the six patients treated over a year (and up to 24 months). None of these patients ever showed any abnormal movements or "on-off" effects.
PATIENTS INCOMPATIBLE WITH L-DOPA
This group comprised 18 patients who were prescribed bromocriptine after having received L-dopa treatment over a long period (Table 3) , either because of lack of effectiveness, drop in efficiency after three to six years (four cases), non-effectiveness of L-dopa given alone (4 g per day) (one case), insufficient action of L-dopa (600 mg daily (one case), or because of side effects of L-dopa, such as acute confusion (two cases), digestive disorders (one case), tachycardia and palpitations (one case), painful contractions of the lower limbs (two cases), or serious dyskinesia without "on-off" effects (six cases). When bromocriptine treatment was started, L-dopa was discontinued whenever possible.
A summary of the results is given in Table 3 . In the subgroups who showed loss in efficiency the one "failure" (case 32) was caused by digestive intolerance with 40 mg of bromocriptine. There were two "excellent" results after stopping L-dopa treatment, bromocriptine alone being very effective for several months. One of the cases (3) showed further improvement which is still maintained after more than 21 months with the same quality. In the other (14), the improvement was only transitory since after eight months the effect of bromocriptine was insufficient at 30 mg, and it became necessary to add L-dopa (600 mg).
The results obtained in the subgroups showing side effects were four "good" results-cardiac disorders (case 11), painful muscle contractions (case 16), acute confusion (case 34) caused by L-dopa.
In these patients, the effectiveness of bromocriptine was equivalent to that of L-dopa and the side effects of the latter did not reappear.
There were two "failures". In one case (31) there were digestive complications (nausea, acidity, and vomiting) and in the other (35) Various mechanisms have been proposed to explain the on-off effects: variations in gastrointestinal absorption of L-dopa during nysthemeresis, appearance of abnormal L-dopa metabolites such as tetrahydropapaveroline (Simon et al., 1971) or of methoxylated derivatives (Lhermitte et al., 1977) , and finally variation in receptor sensitivity (Pycock and Marsden, 1977) . The persistence of on-off effects with bromocriptine leads us to think that there is a variation in the sensitivity (or a hypersensitivity) of the striatal dopaminergic receptors which must play an important role in the physiopathology of the effects.
PATIENTS WITH ADVANCED PARKINSONISM
These three patients, aged between 62 and 68 years, had had the illness from five to 18 years, were all rated 4 on the Hoehn and Yahr (1967) scale, were no longer receiving any beneficial effects from L-dopa nor from other antiParkinsonism therapies, and had all shown dementia for several months.
In all three cases, the administration of 30-32.5 mg of bromocriptine and withdrawal of Ldopa brought about only a very partial improvement that was at best transitory (three to six months). In spite of continued bromocriptine treatment, the therapeutic effect was reduced to zero after this period. In two cases, the patients died after the end of the trials (Table 5) .
In this small group the substitution of L-dopa for bromocriptine was not effective for an adequate period. It should be noted, however, that the doses used (30-32.5 mg) are low compared to those used by Lieberman et al. (1976b) Calne et al. (1974a, b) , Agnoli et al. (1976) , Kartzinel et al. (1976) , Parkes et al. (1976) and Kristensen and Hansen (1977) . We did not, however, observe, as did Gautier and Durand (1977) any cutaneous disorders, sensations of ocular discomfort, or constipation. There was no effect on blood pressure. Bromocriptine administration did not induce any modifications in the biological constants of the blood or of the urine. The EEG was unchanged.
Discussion
Bromocriptine was found to be effective in 34 out of 44 cases (22 "excellent" or "good" results, and 12 "useful" or "mediocre" results). Bromocriptine reduced a number of the inconveniences of L-dopa-improvement of certain side effects (in particular cardiac and painful contractions), reduction of dyskinesia, and renewed response in patients where L-dopa no longer had any useful action but before the onset of intellectual deterioration. Bromocriptine would, therefore, seem to be particularly useful when the effect of L-dopa starts to diminish before the appearance of physical and intellectual decay. In very advanced stages of the illness, however, (psychological and physical decay with ineffectiveness of L-dopa) bromocriptine does not give very useful results.
In the very difficult problem of the treatment of Parkinson's disease with on-off effects, with or without a shuffling walk, bromocriptine reduced their frequency and their intensity and allowed the dose of L-dopa to be reduced by 30-90%. It was, however, no more than an attenuation and the use of this drug does not provide a solution to this problem.
Pharmacologically, the advantages of the dopaminergic agonist bromocriptine over L-dopa indicates two important mechanisms: (1) its action on the postsynaptic dopaminergic receptor, and (2) a saving in the intraneuronal consumption of dopa-decarboxylase. For these reasons bromocriptine could be useful as the first treatment in Parkinson's disease. As the illness develops and the transformation of exogenous L-dopa to dopamine striatal neurones becomes insufficient, bromocriptine can take over by acting at another pole of the synaptic complex. At a more advanced stage, it may be postulated that L-dopa and bromocriptine are no longer effective because of the degeneration of the neurones and the dopaminergic receptors.
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